Should I buy or sell Amicus Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks .

What is Amicus Therapeutics' stock price target for 2024?

3 analysts have issued 12-month price targets for Amicus Therapeutics' stock. Their FOLD share price targets range from $19.00 to $22.00. On average, they expect the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts .

How have FOLD shares performed in 2024?

Amicus Therapeutics' stock was trading at $14.19 at the beginning of 2024. Since then, FOLD shares have decreased by 25.8% and is now trading at $10.53. View the best growth stocks for 2024 here .

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our FOLD earnings forecast .

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.05. The biopharmaceutical company had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 37.96%.

What ETFs hold Amicus Therapeutics' stock?

ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , Global X Guru Index ETF (GURU) , Virtus LifeSci Biotech Products ETF (BBP) , WisdomTree BioRevolution Fund (WDNA) , iShares U.S. Pharmaceuticals ETF (IHE) , SPDR S&P Biotech ETF (XBI) , Principal Healthcare Innovators ETF (BTEC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH) .

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com . John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA) , AcelRx Pharmaceuticals (ACRX) , Gilead Sciences (GILD) , Sangamo Therapeutics (SGMO) , Sarepta Therapeutics (SRPT) , AbbVie (ABBV) , Exelixis (EXEL) , Advanced Micro Devices (AMD) , Inovio Pharmaceuticals (INO) and Novavax (NVAX) .

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.04%), Diversified Trust Co (0.02%), Allspring Global Investments Holdings LLC (0.01%) and Fulton Bank N.A. (0.00%). Insiders that own company stock include Bradley L Campbell , Bradley L Campbell , Burke W Whitman, Burke W Whitman , Daphne Quimi, David Michael Clark , Ellen Rosenberg , Ellen Rosenberg , Jeff Castelli , John F Crowley, John F Crowley , Lynn Dorsey Bleil , Margaret G Mcglynn , Michael Raab and Samantha Prout . View institutional ownership trends .

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free FOLD Stock Alerts

$10.51

+0.18 (+1.74%)

(As of 03:34 PM ET)

Compare

Today's Range: $10.24
▼
$10.66
50-Day Range: $10.33
▼
$14.00
52-Week Range: $9.70
▼
$14.57

Volume: 1.69 million shs
Average Volume: 2.99 million shs
Market Capitalization: $3.10 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.00

Get Amicus Therapeutics alerts:

Amicus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 89.9% Upside
$20.00 Price Target
Short Interest: Bearish
11.00% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.28
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$1.35 M Sold Last Quarter
Proj. Earnings Growth: 3,300.00%
From $0.01 to $0.34 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.73 out of 5 stars

Medical Sector

226th out of 918 stocks

Pharmaceutical Preparations Industry

89th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Amicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Amicus Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.00% of the outstanding shares of Amicus Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Amicus Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Amicus Therapeutics has recently increased by 0.28%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Amicus Therapeutics does not currently pay a dividend.
Dividend Growth
Amicus Therapeutics does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Amicus Therapeutics is -1.28.

2.1

News and Social Media Coverage

News Sentiment
Amicus Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Amicus Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 5 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,346,447.00 in company stock.
Percentage Held by Insiders
Only 2.10% of the stock of Amicus Therapeutics is held by insiders.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Amicus Therapeutics are expected to grow by 3,300.00% in the coming year, from $0.01 to $0.34 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amicus Therapeutics is -20.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amicus Therapeutics is -20.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Amicus Therapeutics has a P/B Ratio of 19.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Amicus Therapeutics Stock (NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

FOLD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FOLD Stock News Headlines

April 14, 2024 | nasdaq.com

Amicus Therapeutics Becomes Oversold (FOLD)

March 30, 2024 | msn.com

Nevada’s Lee joins on to Amicus Brief in SCOTUS abortion case

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 29, 2024 | msn.com

Nevada’s Lee, Cortez Masto join on to Amicus Brief in SCOTUS abortion case

March 20, 2024 | globenewswire.com

Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report

March 16, 2024 | ca.finance.yahoo.com

FOLD Jul 2024 12.000 call

March 7, 2024 | finance.yahoo.com

FOLD Oct 2024 12.000 call

March 7, 2024 | finance.yahoo.com

FOLD Jan 2025 12.000 put

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 7, 2024 | finance.yahoo.com

FOLD Jul 2024 9.000 put

March 7, 2024 | finance.yahoo.com

Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)

March 6, 2024 | finance.yahoo.com

Amicus Therapeutics Stock Sees RS Rating Improve To 74

March 2, 2024 | finance.yahoo.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

March 1, 2024 | seekingalpha.com

Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript

March 1, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV)

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Amicus’s Strong Product Launch and Growth Trajectory

March 1, 2024 | finance.yahoo.com

Amicus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

March 1, 2024 | globenewswire.com

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024

February 29, 2024 | finance.yahoo.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript

February 29, 2024 | seekingalpha.com

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

February 29, 2024 | finance.yahoo.com

Q4 2023 Amicus Therapeutics Inc Earnings Call

February 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Amicus with Strong Growth and Promising Outlook

February 28, 2024 | finanznachrichten.de

Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates

February 28, 2024 | finance.yahoo.com

Amicus Therapeutics Inc (FOLD) Reports 21% Revenue Growth in 2023, Eyes Non-GAAP Profitability ...

February 28, 2024 | msn.com

Amicus Therapeutics Non-GAAP EPS of $0.01 beats by $0.05, revenue of $115.08M in-line

February 28, 2024 | seekingalpha.com

Amicus Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

February 28, 2024 | globenewswire.com

Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates

See More Headlines

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:FOLD
CUSIP: 03152W10
CIK: 1178879
Web: www.amicusrx.com
Phone: (215) 921-7600
Fax: 609-662-2001
Employees: 517
Year Founded: 2002

Price Target and Rating

Average Stock Price Target: $20.00
High Stock Price Target: $22.00
Low Stock Price Target: $19.00
Potential Upside/Downside: +89.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 1,053.00
P/E Growth: N/A
Net Income: $-151,580,000.00
Net Margins: -37.96%
Pretax Margin: -37.59%
Return on Equity: -119.46%
Return on Assets: -20.40%

Debt

Debt-to-Equity Ratio: 2.42
Current Ratio: 2.88
Quick Ratio: 2.52

Sales & Book Value

Annual Sales: $399.36 million
Price / Sales: 7.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.55 per share
Price / Book: 19.15

Miscellaneous

Outstanding Shares: 295,383,000
Free Float: 289,180,000
Market Cap: $3.11 billion
Optionable: Optionable
Beta: 0.75

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Bradley L. Campbell M.B.A. (Age 48)
CEO, President & Director
Comp: $984.09k
Ms. Ellen S. Rosenberg (Age 61)
Chief Legal Officer & Corporate Secretary
Comp: $733.94k
Mr. David M. Clark (Age 49)
Chief People Officer
Comp: $701.39k
Dr. Jeffrey P. Castelli (Age 52)
Chief Development Officer
Comp: $709.64k
Mr. Simon Nicolas Reade Harford (Age 64)
Chief Financial Officer
Ms. Samantha Prout (Age 46)
Chief Accounting Officer & Controller
Dr. Jill Weimer Ph.D.
Chief Science Officer
Andrew Faughnan
Senior Director of Investor Relations
Mr. Patrik S. Florencio Esq.
Global Chief Compliance & Risk Officer
Ms. Diana Moore
Head of Global Corporate Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FOLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings or view top-rated stocks.
What is Amicus Therapeutics' stock price target for 2024?: 3 analysts have issued 12-month price targets for Amicus Therapeutics' stock. Their FOLD share price targets range from $19.00 to $22.00. On average, they expect the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price.
View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts.
How have FOLD shares performed in 2024?: Amicus Therapeutics' stock was trading at $14.19 at the beginning of 2024. Since then, FOLD shares have decreased by 25.8% and is now trading at $10.53.
View the best growth stocks for 2024 here.
When is Amicus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FOLD earnings forecast.
How were Amicus Therapeutics' earnings last quarter?: Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.05. The biopharmaceutical company had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 37.96%.
What ETFs hold Amicus Therapeutics' stock?: ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Guru Index ETF (GURU), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), iShares U.S. Pharmaceuticals ETF (IHE), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?: 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Amicus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).
Who are Amicus Therapeutics' major shareholders?: Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.04%), Diversified Trust Co (0.02%), Allspring Global Investments Holdings LLC (0.01%) and Fulton Bank N.A. (0.00%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends.
How do I buy shares of Amicus Therapeutics?: Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FOLD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amicus Therapeutics (FOLD) Stock Price, News & Analysis

Amicus Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Amicus Therapeutics Stock (NASDAQ:FOLD)

FOLD Stock Price History

FOLD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

FOLD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™